These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 37502925)
21. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Glaviano A; Wander SA; Baird RD; Yap KC; Lam HY; Toi M; Carbone D; Geoerger B; Serra V; Jones RH; Ngeow J; Toska E; Stebbing J; Crasta K; Finn RS; Diana P; Vuina K; de Bruin RAM; Surana U; Bardia A; Kumar AP Drug Resist Updat; 2024 Sep; 76():101103. PubMed ID: 38943828 [TBL] [Abstract][Full Text] [Related]
22. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy. He Q; Zhang Y; Li W; Chen S; Xiong J; Zhao R; Yuan K; Hu Q; Liu S; Gao G; Bedford MT; Tang DG; Xu B; Zou C; Zhang D Cancer Lett; 2024 Oct; 602():217214. PubMed ID: 39218291 [TBL] [Abstract][Full Text] [Related]
24. RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models. Kumarasamy V; Nambiar R; Wang J; Rosenheck H; Witkiewicz AK; Knudsen ES Oncogene; 2022 Jul; 41(27):3524-3538. PubMed ID: 35676324 [TBL] [Abstract][Full Text] [Related]
25. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR Sammons S; Shastry M; Dent S; Anders C; Hamilton E Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379 [TBL] [Abstract][Full Text] [Related]
26. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer. Belli S; Esposito D; Ascione CM; Messina F; Napolitano F; Servetto A; De Angelis C; Bianco R; Formisano L Cancer Lett; 2024 Jul; 593():216968. PubMed ID: 38788968 [TBL] [Abstract][Full Text] [Related]
27. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. De Angelis C; Fu X; Cataldo ML; Nardone A; Pereira R; Veeraraghavan J; Nanda S; Qin L; Sethunath V; Wang T; Hilsenbeck SG; Benelli M; Migliaccio I; Guarducci C; Malorni L; Litchfield LM; Liu J; Donaldson J; Selenica P; Brown DN; Weigelt B; Reis-Filho JS; Park BH; Hurvitz SA; Slamon DJ; Rimawi MF; Jansen VM; Jeselsohn R; Osborne CK; Schiff R Clin Cancer Res; 2021 Sep; 27(17):4870-4882. PubMed ID: 33536276 [TBL] [Abstract][Full Text] [Related]
28. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer. Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886 [TBL] [Abstract][Full Text] [Related]
29. Design of SERENA-6, a phase III switching trial of camizestrant in Turner N; Huang-Bartlett C; Kalinsky K; Cristofanilli M; Bianchini G; Chia S; Iwata H; Janni W; Ma CX; Mayer EL; Park YH; Fox S; Liu X; McClain S; Bidard FC Future Oncol; 2023 Mar; 19(8):559-573. PubMed ID: 37070653 [TBL] [Abstract][Full Text] [Related]
30. Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer. Kharenko OA; Patel RG; Calosing C; van der Horst EH Cancer Gene Ther; 2022 Jun; 29(6):859-869. PubMed ID: 34385584 [TBL] [Abstract][Full Text] [Related]
31. PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies. Carter J; Hulse M; Sivakumar M; Burtell J; Thodima V; Wang M; Agarwal A; Vykuntam K; Spruance J; Bhagwat N; Rager J; Ruggeri B; Scherle P; Ito K Cancer Res Commun; 2023 Nov; 3(11):2233-2243. PubMed ID: 37861290 [TBL] [Abstract][Full Text] [Related]
32. Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast Cancer. Mai N; Dos Anjos CH; Razavi P; Safonov A; Patil S; Chen Y; Drago JZ; Modi S; Bromberg JF; Dang CT; Liu D; Norton L; Robson M; Chandarlapaty S; Jhaveri K Res Sq; 2024 May; ():. PubMed ID: 38746324 [TBL] [Abstract][Full Text] [Related]
34. Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer. Zhang C; Zhou F; Zou J; Fang Y; Liu Y; Li L; Hou J; Wang G; Wang H; Lai X; Xie L; Jiang J; Yang C; Huang Y; Chen Y; Zhang H; Li Y Front Oncol; 2023; 13():1322078. PubMed ID: 38293701 [TBL] [Abstract][Full Text] [Related]
35. Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer. Knudsen ES; Witkiewicz AK Oncotarget; 2016 Oct; 7(43):69111-69123. PubMed ID: 27564114 [TBL] [Abstract][Full Text] [Related]
36. Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer. Michaloglou C; Crafter C; Siersbaek R; Delpuech O; Curwen JO; Carnevalli LS; Staniszewska AD; Polanska UM; Cheraghchi-Bashi A; Lawson M; Chernukhin I; McEwen R; Carroll JS; Cosulich SC Mol Cancer Ther; 2018 May; 17(5):908-920. PubMed ID: 29483206 [TBL] [Abstract][Full Text] [Related]
37. Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer. Kim S; Armand J; Safonov A; Zhang M; Soni RK; Schwartz G; McGuinness JE; Hibshoosh H; Razavi P; Kim M; Chandarlapaty S; Yang HW Cell Rep; 2023 Nov; 42(11):113198. PubMed ID: 37865915 [TBL] [Abstract][Full Text] [Related]
38. S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer. Mo H; Liu X; Xue Y; Chen H; Guo S; Li Z; Wang S; Li C; Han J; Fu M; Song Y; Li D; Ma F Mol Cancer; 2022 Aug; 21(1):171. PubMed ID: 36042494 [TBL] [Abstract][Full Text] [Related]
39. Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells. Li S; Zhang Y; Wang N; Guo R; Liu Q; Lv C; Wang J; Wang L; Yang QK Cell Death Dis; 2020 Apr; 11(4):219. PubMed ID: 32249776 [TBL] [Abstract][Full Text] [Related]
40. Decreased ER dependency after acquired resistance to CDK4/6 inhibitors. Iida M; Toyosawa D; Nakamura M; Tsuboi K; Tokuda E; Niwa T; Ishida T; Hayashi SI Breast Cancer; 2020 Sep; 27(5):963-972. PubMed ID: 32297248 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]